(0470–0505) Rheumatoid Arthritis – Treatment Poster I

Sunday, October 26, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

A Phase 2b Dose-ranging Study of Peresolimab for Adults With ra
Abstract Poster Presenter: Michael Weinblatt, MD – Brigham and Women's Hospital/ Harvard Medical School
10:30 AM - 12:30 PM Central Time

An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 anti-cd19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA Positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
Abstract Poster Presenter: Ioanna Minopoulou, MD;MSc – Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
10:30 AM - 12:30 PM Central Time

Association Of short Chain Fatty Acids and diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
Abstract Poster Presenter: Kaci French, MD, MPH – NYU Langone Health
10:30 AM - 12:30 PM Central Time

At the patient level, ultrasound evaluation during the follow up of rheumatoid arthritis does not modify radiographic evolution: a prospective, multicenter, randomized, pragmatic clinical trial (BCD study)
Abstract Poster Presenter: Alexandre GARMENDIA, MD – Université de bretagne occidentale
10:30 AM - 12:30 PM Central Time

Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Abstract Poster Presenter: Mitndbaim Parra Moreno, MD – Reina Sofia University Hospital, Cordoba
10:30 AM - 12:30 PM Central Time

Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Abstract Poster Presenter: Bruno Fautrel, MD, PhD – Sorbonne University - APHP
10:30 AM - 12:30 PM Central Time

Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
Abstract Poster Presenter: Ernest Choy, MD – Cardiff University
10:30 AM - 12:30 PM Central Time

Detrimental Effects of Umbilical Cord Blood-derived Mesenchymal Stem Cells Intra-articular Injections on Pannus Invasiveness
Abstract Poster Presenter: Kichul Shin, MD, PhD – Seoul National University
10:30 AM - 12:30 PM Central Time

Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
10:30 AM - 12:30 PM Central Time

Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Abstract Poster Presenter: Nariaki Hao, PhD – Graduate School of Medical and Dental Sciences, Niigata, Japan
10:30 AM - 12:30 PM Central Time

Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
Abstract Poster Presenter: Jérôme Avouac, MD,PhD – Université de Paris Cité
10:30 AM - 12:30 PM Central Time

Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
Abstract Poster Presenter: MIDHUN SAKRAVARTHY JALANATHAN, Jr, MD (he/him/his) – ESIC Medical College & Hospital, Sanathnagar
10:30 AM - 12:30 PM Central Time

Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
Abstract Poster Presenter: Chan-Bum Choi, MD, PhD, MPH (he/him/his) – Hanyang University Hosptial for Rheumatic Diseases
10:30 AM - 12:30 PM Central Time

Efficacy and safety profile of JAK inhibitors in current practice in rheumatoid arthritis
Abstract Poster Presenter: Jérôme Avouac, MD,PhD – Université de Paris Cité
10:30 AM - 12:30 PM Central Time

Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Abstract Poster Presenter: Hideto Kameda – Toho University
10:30 AM - 12:30 PM Central Time

Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence
Abstract Poster Presenter: Sofia Kuzkina, MD (she/her/hers) – R-Pharm
10:30 AM - 12:30 PM Central Time

Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
Abstract Poster Presenter: Sofia Kuzkina, MD (she/her/hers) – R-Pharm
10:30 AM - 12:30 PM Central Time

Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted - DMARD in RA: A Systematic Review and Network Meta-analysis
Abstract Poster Presenter: Jia Li, MD, PhD (she/her/hers) – Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
10:30 AM - 12:30 PM Central Time

Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
Abstract Poster Presenter: Chandrashekara MN, DM – PGIMER
10:30 AM - 12:30 PM Central Time

Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Abstract Poster Presenter: Sama Hajizadeh, MD – Allegheny Health Network
10:30 AM - 12:30 PM Central Time

LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
Abstract Poster Presenter: Matthew McClure, MD – Lifordi
10:30 AM - 12:30 PM Central Time

Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib
Abstract Poster Presenter: Guillermo Gonzalez Mozo de Rosales, MD – Basurto University Hospital
10:30 AM - 12:30 PM Central Time

Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Abstract Poster Presenter: Roy Fleischmann, MD – Metroplex Clinical Research Center
10:30 AM - 12:30 PM Central Time

Outcomes of Total Knee Replacement in Patients with Rheumatoid Arthritis: A National Inpatient Sample Database Analysis
Abstract Poster Presenter: karun Shrestha, MD – Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY 10457, USA
10:30 AM - 12:30 PM Central Time

Pharmacokinetic Similarity of DRL_AB, a Proposed Biosimilar Abatacept (Orencia®): Results from a Randomized, Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study in Healthy Subjects by the Intravenous Route.
Abstract Poster Presenter: Naveen Reddy MAREDDY, MD (he/him/his) – Biologics, Dr. Reddy’s Laboratories Ltd., Hyderabad, India
10:30 AM - 12:30 PM Central Time

Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety
Abstract Poster Presenter: Sarah Baxter, MD, PhD (she/her/hers) – Sonoma Biotherapeutics
10:30 AM - 12:30 PM Central Time

Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor
Abstract Poster Presenter: Maarten Kraan, MD, PhD (he/him/his) – CDS Advies BV
10:30 AM - 12:30 PM Central Time

R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients
Abstract Poster Presenter: Christian Furlan Freguia, PhD (he/him/his) – Rise Therapeutics
10:30 AM - 12:30 PM Central Time

Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
Abstract Poster Presenter: Ashkan Ara, MD, MPH – UCLA
10:30 AM - 12:30 PM Central Time

Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Abstract Poster Presenter: Satani Sharkas, MD – Boston Medical Center - Brighton
10:30 AM - 12:30 PM Central Time

Real-World Experience of Janus Kinase Inhibitors; Retention and Factors Associated with Discontinuation
Abstract Poster Presenter: Patrick Kiely, MD,PhD,MBBS,BSc,FRCP (he/him/his) – St George's University Hospitals NHS Foundation Trust
10:30 AM - 12:30 PM Central Time

Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Abstract Poster Presenter: Asim Khanfar, MD – Rochester General Hospital
10:30 AM - 12:30 PM Central Time

Safety of JAK inhibitors (JAKi) in chronic inflammatory arthritis (CIA): an observational study
Abstract Poster Presenter: Clara De Miguel, MD – Hospital Clínico San Carlos
10:30 AM - 12:30 PM Central Time

Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
Abstract Poster Presenter: Hideto Kameda – Toho University
10:30 AM - 12:30 PM Central Time

Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
Abstract Poster Presenter: Soon Wei Wong, PhD – College of Medicine and Public Health
10:30 AM - 12:30 PM Central Time

Use of Upadacitinib in Real-World Clinical Practice: Patient Characteristics and Glucocorticoid-Sparing Effect
Abstract Poster Presenter: Virginia Ruiz Esquide, PhD (she/her/hers) – Hospital Clinic de Barcelona